These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 31564903)
1. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer. Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer. Choi JE; Lee JS; Jin MS; Nikas IP; Kim K; Yang S; Park SY; Koh J; Yang S; Im SA; Ryu HS Breast Cancer Res; 2023 Nov; 25(1):134. PubMed ID: 37924153 [TBL] [Abstract][Full Text] [Related]
3. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
4. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer]. Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876 [No Abstract] [Full Text] [Related]
5. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas. Uğurluoğlu C; Yormaz S Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer. Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865 [TBL] [Abstract][Full Text] [Related]
7. Is Programmed Death-Ligand 1 of Prognostic Significance in Triple-Negative Female Mammary Carcinoma? Sanad AM; Ibrahim WS; Ezzo IM; Sabry RM J Microsc Ultrastruct; 2024; 12(1):6-13. PubMed ID: 38633572 [TBL] [Abstract][Full Text] [Related]
8. Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics. Huang X; Wang X; Qian H; Jin X; Jiang G Evid Based Complement Alternat Med; 2021; 2021():5314016. PubMed ID: 34721634 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus. Zapała Ł; Kunc M; Sharma S; Pęksa R; Popęda M; Biernat W; Radziszewski P J Cancer Res Clin Oncol; 2023 Jul; 149(7):4131-4139. PubMed ID: 36042047 [TBL] [Abstract][Full Text] [Related]
10. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population. Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583 [TBL] [Abstract][Full Text] [Related]
11. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer. Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433 [TBL] [Abstract][Full Text] [Related]
12. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target. Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176 [TBL] [Abstract][Full Text] [Related]
13. Expression and Clinical Significance of Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949 [TBL] [Abstract][Full Text] [Related]
14. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma. Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
16. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773 [TBL] [Abstract][Full Text] [Related]
17. The expression of programmed death-ligand 1 in patients with invasive breast cancer. Meng Y; Wu H; Yao Y; Li R Gland Surg; 2020 Dec; 9(6):2106-2115. PubMed ID: 33447561 [TBL] [Abstract][Full Text] [Related]
18. p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer. Xing AY; Liu L; Liang K; Wang B Cancer Invest; 2022 Nov; 40(10):879-888. PubMed ID: 35980253 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717 [TBL] [Abstract][Full Text] [Related]
20. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]